Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope–based grass pollen allergy vaccine with allergen extract–based vaccines

Journal of Allergy and Clinical Immunology

Volumn 140, Issue 5, 2017, Pages 1433-1436.e6

  Weber, Milena ^a   Niespodziana, Katarzyna ^a   Linhart, Birgit ^a   Neubauer, Angela ^b   Huber, Hans ^b   Henning, Rainer ^b   Valenta, Rudolf ^a   Focke Tejkl, Margarete ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b BIOMAY AG   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE ANTIGEN; BM 32; EPITOPE; GRASS POLLEN EXTRACT; GRASS POLLEN VACCINE; IMMUNOGLOBULIN G ANTIBODY; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; ALLERGEN; ALUMINUM HYDROXIDE; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; PLANT PROTEIN; VACCINE;

ANTIBODY RESPONSE; ARTICLE; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GRASS POLLEN; POLLEN ALLERGY; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION; VACCINE IMMUNOGENICITY; ANIMAL; HUMAN; IMMUNOLOGY; LEPORIDAE; POACEAE; POLLEN;

ADJUVANTS, IMMUNOLOGIC; ALLERGENS; ALUMINUM HYDROXIDE; ANIMALS; EPITOPES, B-LYMPHOCYTE; HUMANS; IMMUNOGLOBULIN G; PLANT PROTEINS; POACEAE; POLLEN; RABBITS; RHINITIS, ALLERGIC, SEASONAL; VACCINES;

EID: 85021192145     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2017.03.048     Document Type: Article

References (20)

1. Cox, L., Calderón, M., Pfaar, O., Subcutaneous allergen immunotherapy for allergic disease: examining efficacy, safety and cost-effectiveness of current and novel formulations. Immunotherapy 4 (2012), 601–616.
2. Keil, M.A., Röder, E., Gerth van Wijk, R., Al, M.J., Hop, W.C., Rutten-van Mölken, M.P., Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol 132 (2013), 353–360.
3. Focke-Tejkl, M., Weber, M., Niespodziana, K., Neubauer, A., Huber, H., Henning, R., et al. Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy. J Allergy Clin Immunol 135 (2015), 1207–1217 e1-11.
4. Zieglmayer, P., Focke-Tejkl, M., Schmutz, R., Lemell, P., Zieglmayer, R., Weber, M., et al. Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy. EBioMedicine 11 (2016), 43–57.
5. Westritschnig, K., Horak, F., Swoboda, I., Balic, N., Spitzauer, S., Kundi, M., et al. Different allergenic activity of grass pollen allergens revealed by skin testing. Eur J Clin Invest 38 (2008), 260–267.
6. Cornelius, C., Schöneweis, K., Georgi, F., Weber, M., Niederberger, V., Zieglmayer, P., et al. Immunotherapy with the PreS-based grass pollen allergy vaccine BM32 induces antibody responses protecting against hepatitis B Infection. EBioMedicine 11 (2016), 58–67.
7. Larché M., Akdis, C.A., Valenta, R., Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 6 (2006), 761–771.
8. Rosewich, M., Schulze, J., Eickmeier, O., Telles, T., Rose, M.A., Schubert, R., et al. Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children. Clin Exp Immunol 160 (2010), 403–410.
9. Mothes, N., Heinzkill, M., Drachenberg, K.J., Sperr, W.R., Krauth, M.T., Majlesi, Y., et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 33 (2003), 1198–1208.
10. Marth, K., Focke, M., Flicker, S., Valenta, R., Human monoclonal antibody-based quantifications of group 2 grass pollen allergens. J Allergy Clin Immunol 113 (2004), 470–474.
11. Drachenberg, K.J., Wheeler, A.W., Stuebner, P., Horak, F., A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 56 (2001), 498–505.
12. Focke-Tejkl, M., Weber, M., Niespodziana, K., Neubauer, A., Huber, H., Henning, R., et al. Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy. J Allergy Clin Immunol 135 (2015), 1207–1217 e1-11.
13. Towbin, H., Staehelin, T., Gordon, J., Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 76 (1979), 4350–4354.
14. Valenta, R., Duchene, M., Ebner, C., Valent, P., Sillaber, C., Deviller, P., et al. Profilins constitute a novel family of functional plant pan-allergens. J Exp Med 175 (1992), 377–385.
15. Focke, M., Mahler, V., Ball, T., Sperr, W.R., Majlesi, Y., Valent, P., et al. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. FASEB J 15 (2001), 2042–2044.
16. Jutel, M., Agache, I., Bonini, S., Burks, A.W., Calderon, M., Canonica, W., et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol 136 (2015), 556–568.
17. Jacobsen, L., Niggemann, B., Dreborg, S., Ferdousi, H.A., Halken, S., Host, A., et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 62 (2007), 943–948.
18. Casale, T.B., Stokes, J.R., Immunotherapy: what lies beyond. J Allergy Clin Immunol 133 (2014), 612–619.
19. Niederberger, V., Marth, K., Eckl-Dorna, J., Focke-Tejkl, M., Weber, M., Hemmer, W., et al. Skin test evaluation of a novel peptide carrier-based vaccine, BM32, in grass pollen-allergic patients. J Allergy Clin Immunol 136 (2015), 1101–1103.
20. Paul, W.E., Katz, D.H., Goidl, E.A., Benacerraf, B., Carrier function in anti-hapten immune responses. II. Specific properties of carrier cells capable of enhancing anti-hapten antibody responses. J Exp Med 132 (1970), 283–299.